Case Page

 

Case Status:    ONGOING    
On or around 07/21/2017 (Ongoing date of last review)

Filing Date: February 17, 2017

According to the law firm press release, the complaint alleges that defendants caused the Company to issue materially misleading statements and/or omit material information concerning the Company's second Phase III study for MDX in adults with attention deficit hyperactivity disorder ("ADHD"), the "MDX Evaluation in Adults – Study of Response and Efficacy," or the "MEASURE" study. The complaint alleges these misstatements and omissions by Alcobra violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 21, 2017, the Court appointed Lead Plaintiffs and Counsel.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Israel

SECURITIES INFORMATION:

Ticker Symbol: ADHD
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 17-CV-01233
JUDGE: Hon. J. Paul Oetken
DATE FILED: 02/17/2017
CLASS PERIOD START: 08/13/2015
CLASS PERIOD END: 01/17/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Lifshitz & Miller
    821 Franklin Avenue, Suite 209 , Lifshitz & Miller, NY 11530
    (516) 493-9780 (516) 280-7376 ·
No Document Title Filing Date